ClinicalTrials.gg
RecruitingNCT07696546PEGUpdated Jul 10, 2026

Randomized Trial of Percutaneous vs. Endoscopic Gallbladder Drainage

An interventional study of Percutaneous cholecystostomy and EUS-guided gallbladder drainage in Acute Cholecystitis, sponsored by Orlando Health, Inc.. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-10.

Sponsored by Orlando Health, Inc. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Cholecystitis, Acute with a site in United States — 5 open to participants now, 5 under way, none of them phase 3. Cholecystitis, Acute · United States.

Planned enrollment
3rd of 10
110 · median 49
Started
2026
with 2 others
No phase
9 of 17
4 open now
Registered
15th of 17
by date
Lead sponsor
1 of 17
Orlando Health, Inc.

Among the 17 studies in Cholecystitis, Acute with a site in United States, this one is the 3rd largest by planned enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2026, is one of 9 with no phase, and was the 15th registered.

Cholecystitis, Acute

140 studies on the registry are indexed under Cholecystitis, Acute; 30 are open to participants now.

Browse Cholecystitis, Acute studies →

Open to participants now

5 of the 17 studies in Cholecystitis, Acute with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 21 Cholecystitis, Acute studies recruiting now, 17 (81%) set no upper age limit and 2 (10%) stop at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Cholecystitis, Acute with a site in United States, or all of them as a file.
02

Study summary

This is a randomized trial of patients with acute calculous cholecystitis who are never-surgery candidates. Patients will be randomized to one of two treatment groups, percutaneous cholecystostomy or endoscopic ultrasound-guided drainage. The aim of the study is to compare between these two treatment methods, the treatment outcomes and quality of life over a follow-up duration of 36 months.

Read the detailed description

Acute calculous cholecystitis (ACC) is characterized by an inflammatory condition involving the gallbladder wall, most often caused by an obstruction at the infundibulum or cystic duct, with less than 10% of cases provoked by other causes.

Surgical cholecystectomy (SC), especially by laparoscopic assistance, is considered the gold standard approach for the treatment of ACC. However, some patients due to high frailty, multiple comorbidities, and clinically significant organ failure are considered suboptimal or "unfit" candidates for surgery. Therefore, less invasive approaches have been developed for this challenging population.

Percutaneous choleystostomy (PC) has been traditionally considered the first alternative in patients who are not considered for surgery, as it is a less invasive approach with lower rates of complications compared to SC. The procedure is considered technically easy for experienced interventional radiologists and is based on the insertion of a percutaneous catheter in the gallbladder under fluoroscopic assistance after an ultrasound-guided puncture with an 18-gauge needle. Nevertheless, like any other procedure, PC is not exempt from complications, such as bleeding, pneumothorax, peritonitis, injury to adjacent organs, pain at the site of insertion, catheter dislodgement, and risk for recurrent cholecystitis upon removal of the catheter.

Endoscopic ultrasound (EUS)-guided gallbladder drainage (EUS-GBD) has been described as another minimally invasive option for these patients. Under endoscopic ultrasound-guidance, a lumen-apposing metal stent is placed within the gallbladder lumen from the stomach or the duodenum (EUS-GBD), thus allowing internal drainage. EUS-GBD appears to have some benefits over PC, since the latter is typically associated with patient's discomfort and pain at the site of insertion, and carries inherent disadvantages associated with external drainage.

The management of ACC in patients who are not surgical candidates is complex. These patients carry a high risk of peri-cholecystectomy and post-cholecystectomy complications and a mortality rate of up to 19%. The initial management of patients who are not surgical candidates consists of antibiotic therapy and minimally invasive procedures for adequate gallbladder drainage. These procedures include PC and endoscopy-guided gallbladder drainage. Tokyo Guidelines-2018 (TG-18) recommend PC as the standard drainage method for surgically high-risk patients with AC. World Society of Emergency Surgery 2020 guidelines recommend considering endoscopic transpapillary gallbladder drainage (ET-GBD) or EUS-GBD as an alternative to PC in high-volume centers when performed by skilled endoscopists. There is a lumen-apposing metal stent (LAMS), which was recently approved by the Food and Drug Administration (FDA) for EUS-GBD in poor surgical candidates.

In a prior study (DRAC 1) that compared PC versus EUS-GBD in high-risk patients with ACC, EUS-GBD was associated with significantly fewer adverse events, readmissions and recurrent cholecystitis. However, the follow-up duration was only 12 months, which is a very short timeframe to reliably compare long-term outcomes between modalities. This is particularly relevant as nearly 45% of patients who do not receive a cholecystectomy die within 825 days of an attack of ACC. Also, health-related quality of life and treatment costs were not assessed in DRAC 1. Finally, the primary outcome in the DRAC 1 trial was only a single measure - adverse events. The burden of ACC and the impact of treatment is more accurately measured using a composite endpoint encompassing readmissions and reinterventions in addition to adverse events.

We hypothesize that by performing EUS-GBD as the first-line therapy in never-surgery patients presenting with ACC, the rates of procedural reinterventions, readmissions, and disease or procedure-related adverse events can be reduced as compared to patents undergoing percutaneous cholecystostomy.

03

Conditions studied

  • Acute Cholecystitis

Browse trials for

Keywords

  • EUS-guided gallbladder drainage
  • percutaneous cholecystostomy
  • Acute calculous cholecystitis
  • Endoscopic ultrasound
  • Interventional radiology
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with suspected or confirmed acute calculous cholecystitis, diagnosed per Tokyo guidelines
  • Age ≥ 18 years
  • Patients due to severe comorbidity who are deemed to be never-surgery candidates by the multidisciplinary team or patients who refuse to undergo surgery.
  • Patients can undergo EUS-guided drainage and percutaneous cholecystostomy tube placement.
  • Written by the patient or guardian who can understand the nature and possible consequences of participation in the study.

Exclusion criteria

Exclusion Criteria:

  • Pregnancy
  • Patients who are potential candidates for future cholecystectomy.
  • Patients unwilling to undergo follow-up assessments.
  • Patients with suspected gangrene or perforation of the gallbladder
  • Patients are diagnosed with concomitant liver abscess or necrotizing pancreatitis.
  • Altered anatomy of the upper gastrointestinal tract due to surgery of the esophagus, stomach and duodenum.
  • Indwelling percutaneous cholecystostomy tube.
  • /persistently significant ascites despite paracentesis.
  • Distance between the gallbladder and gastric/duodenal wall that cannot be bridged by the metal stent.
  • Abnormal coagulation parameters that cannot be correct: > 1.7 and/or \< 50.000/mm3
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
110 participants (estimated)

Study arms

  • Active comparator
    Percutaneous cholecystostomy

    Patients with acute calculous cholecystitis who are never-surgery candidates undergoing percutaneous cholecystostomy tube placement

    Procedure: Percutaneous cholecystostomy

  • Active comparator
    EUS-guided gallbladder drainage

    Patients with acute calculous cholecystitis who are never-surgery candidates, undergoing EUS-guided gallbladder drainage

    Procedure: EUS-guided gallbladder drainage

Interventions

  • ProcedurePercutaneous cholecystostomy

    Percutaneous cholecystostomy tube placement by interventional radiology

  • ProcedureEUS-guided gallbladder drainage

    EUS-guided gallbladder drainage using metal stent

06

What researchers measure

Primary outcomes

  1. Composite endpoint of 1) procedure-related adverse events, 2) reintervention for disease recurrence or procedure-related adverse events, and/or 3) readmission due to underlying disease or procedure-related adverse events

    A composite endpoint of 1) procedure-related adverse events, 2) reintervention for disease recurrence or procedure-related adverse events, and/or 3) readmission due to underlying disease or procedure-related adverse events, from index procedure to 36 months post-index intervention.

    Time frame: 36 months

Secondary outcomes

  1. Mortality

    Rate of mortality at 30 days post-index intervention due to underlying disease.

    Time frame: 30 days

  2. Procedure-related adverse events

    Rate of procedure-related adverse events, defined as adverse events resulting from the endoscopic or radiological procedures performed. Procedure-related adverse events will be graded according to Clavien-Dindo classification.

    Time frame: 36 months

  3. Disease-related adverse events

    Rate of disease-related adverse events, defined as adverse events resulting from underlying acute cholecystitis (such as gallbladder perforation, sepsis).

    Time frame: 36 months

  4. New onset single and multiple organ failure.

    Rate of new onset single and multiple organ failure.

    Time frame: 36 months

  5. New onset systemic dysfunction.

    Rate of new onset systemic dysfunction.

    Time frame: 36 months

  6. Intraabdominal bleeding.

    Rate of intraabdominal bleeding.

    Time frame: 36 months

  7. Leakage of bile from the gallbladder or the biliary tract.

    Rate of leakage of bile from the gallbladder or the biliary tract.

    Time frame: 36 months

  8. Perforation of a visceral organ requiring interventional procedure.

    Rate of perforation of a visceral organ requiring interventional procedure.

    Time frame: 36 months

  9. Stent or percutaneous catheter-related complications

    Rate of stent or percutaneous catheter-related complications, such as percutaneous catheter (cholecystostomy tube) insertion site infection, percutaneous catheter dislodgement.

    Time frame: 36 months

  10. Disease recurrence

    Rate of disease recurrence, which includes acute cholecystitis or biliary colic.

    Time frame: 36 months

  11. Need for reintervention

    Rate of reintervention (reintervention defined as any unplanned endoscopic, radiological or surgical intervention performed following index intervention due to recurrent or persistent symptoms or acute cholecystitis).

    Time frame: 36 months

  12. Total number of reinterventions performed

    Total number of reinterventions performed, including endoscopic, surgical and radiological interventions.

    Time frame: 36 months

  13. Length of hospitalization

    Length of hospitalization, including length of ICU stay.

    Time frame: 36 months

  14. Readmissions

    Rate of readmissions due to symptoms from underlying disease or procedure-related adverse events.

    Time frame: 36 months

  15. New onset SIRS at 24, 48 and 72 hours, post-index intervention.

    Rate of New onset SIRS at 24, 48 and 72 hours, post-index intervention.

    Time frame: 72 hours

  16. Resolution and improvement of SIRS at 24, 48 and 72 hours, post-index intervention.

    Rate of Resolution and improvement of SIRS at 24, 48 and 72 hours, post-index intervention.

    Time frame: 72 hours

  17. Technical success

    Rate of Technical success, defined as the successful placement of metal stent or percutaneous catheter.

    Time frame: 36 months

  18. Clinical success

    Rate of Clinical success, defined as resolution of symptoms and normalization of laboratory parameters prior to hospital discharge after index intervention.

    Time frame: 36 months

  19. Health-related quality of life (HRQoL) scores

    Health-related quality of life (HRQoL) scores as assessed by the Medical Outcomes Study 36-Item Short-Form General Health Survey (SF-36) at randomization, discharge, 1 month, 3 months, 6 months, 12 months, 18 months, 24 months, 30 months and 36 months after index intervention.

    Time frame: 36 months

  20. Overall treatment costs from index intervention until hospital discharge.

    Overall treatment costs from index intervention until hospital discharge. All relevant costs pertaining to treatment will be taken into consideration - procedure costs, inpatient hospital stay from date of procedure to discharge, medications, materials, anesthesia, pharmacy and imaging studies.

    Time frame: 36 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Jun 2032, 71 months later.

Of 43 non-industry interventional studies with no phase under Cholecystitis, Acute, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 24. This study's planned 71 months is above that.

Counting every sponsor, half of 46 studies reached it within 20 months; a quarter within 9 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2026
First posted
Jul 10, 2026
StartEst.
Jul 2026
Primary completionEst.
Jun 2032
CompletionEst.
Dec 2032
Last update
Jul 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07696546
Lead sponsor
Orlando Health, Inc.
Responsible party
Sponsor
First posted
Jul 10, 2026
Start date
Jul 2026 (estimated)
Primary completion
Jun 2032 (estimated)
Completion
Dec 2032 (estimated)
Last update
Jul 10, 2026

Study contacts

Ji Young Bang, MD MPH
Contact
jiyoung.bang@orlandohealth.com
321-842-2273
Barbara J Broome
Contact
barbara.broome@orlandohealth.com
321-841-4356
Ji Young Bang, MD MPH
principal investigator · Orlando Health, Digestive Health Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion